Media headlines about Alliqua Biomedical (NASDAQ:ALQA) have been trending positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alliqua Biomedical earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave news articles about the company an impact score of 44.3768477813292 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Several research analysts have issued reports on ALQA shares. ValuEngine upgraded Alliqua Biomedical from a “sell” rating to a “hold” rating in a research report on Friday, October 6th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Alliqua Biomedical in a research note on Monday, September 18th. Finally, Zacks Investment Research raised Alliqua Biomedical from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a research note on Tuesday, September 12th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $11.25.

Alliqua Biomedical (NASDAQ ALQA) opened at $1.90 on Friday. Alliqua Biomedical has a 52 week low of $1.90 and a 52 week high of $8.50.

COPYRIGHT VIOLATION WARNING: This article was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://theolympiareport.com/2017/12/16/alliqua-biomedical-alqa-given-daily-coverage-optimism-rating-of-0-25.html.

About Alliqua Biomedical

Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.

Insider Buying and Selling by Quarter for Alliqua Biomedical (NASDAQ:ALQA)

Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with Analyst Ratings Network's FREE daily email newsletter.